Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: September 5, 2007
Last updated: May 10, 2013
Last verified: May 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2012
  Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)